Evidence map›Paper›PMID 40046783›Full record

SynthesisFrontiers in aging neuroscience2025

Efficacy of transcranial direct current stimulation on cognitive function in patients with Parkinson's disease: a systematic review and meta-analysis.

Shenhong Ma, Weisheng Zhuang, Xu Wang, Di Zhang, Heling Wang, Qiaohua Han, Qixin Ding, Yuefang Li, Wanyue Li, Tianshu Li

Abstract readSystematic Review
In one paragraph

Synthesis in Frontiers in aging neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Neurotransmitter Systems in Alzheimer's Disease.Current issues in molecular biology · 2026
    Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Shenhong MaSchool of Rehabilitation Medicine, Henan University of Chinese Medicine, Zhengzhou, China.
Weisheng ZhuangDepartment of Rehabilitation, Henan Provincial People's Hospital, School of Rehabilitation Medicine, Henan University of Chinese Medicine, Zhengzhou, China.
Xu WangSchool of Rehabilitation Medicine, Henan University of Chinese Medicine, Zhengzhou, China.
Di ZhangSchool of Rehabilitation Medicine, Henan University of Chinese Medicine, Zhengzhou, China.
Heling WangSchool of Rehabilitation Medicine, Henan University of Chinese Medicine, Zhengzhou, China.
Qiaohua HanSchool of Clinical Medicine, Henan University, Zhengzhou, China.
Qixin DingSchool of Rehabilitation Medicine, Henan University of Chinese Medicine, Zhengzhou, China.
Yuefang LiSchool of Clinical Medicine, Henan University, Zhengzhou, China.
Wanyue LiDepartment of Radiology, Henan Provincial People's Hospital, Zhengzhou, China.
Tianshu LiZhengzhou First People's Hospital, Zhengzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To assess the therapeutic effect of tDCS on cognitive function in patients with Parkinson's disease. Methods: From the start of the library's construction until June 24, 2024, we searched the following databases for literature: PubMed, Embase, Web of Science, Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang, China Science and Technology Journal Database (VIP), and China Biomedical Literature Database (CBM). We also looked through the references in the articles. The improvement of overall cognition in patients with Parkinson's disease with tDCS was the primary outcome indicator. The improvement of executive function, memory, attention, language, quality of life, and depression with tDCS were the secondary outcome indicators. Two researchers extracted data independently, with a third researcher mediating in the event of a dispute. The Cochrane risk of bias tool was used to evaluate the quality of the included literature. Results: A total of 23 articles encompassing 874 subjects were included. tDCS has shown significant efficacy on overall cognition (SMD = 0.73, 95% CI = 0.57 to 0.89, I Conclusion: tDCS demonstrated substantial efficacy in enhancing overall cognition in patients with PD. The efficacy of tDCS was obvious in executive function, language, and depressive mood. Nonetheless, a substantial quantity of rigorous clinical trials on tDCS for cognitive function in patients with PD remains necessary in the future.

Indexed as

cognitive functionmeta-analysisParkinson's diseaserandomized controlled trialtDCS

Identifiers

PMID40046783
PMCPMC11880240

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.